Physician profile
Staeci Lee
NPI 1336628312
$7,184.28
in general payments reported to CMS, 2019-2025
24 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $1,177 · 2023: $3,422 · 2024: $1,105 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,847 · Travel and Lodging: $1,947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,847.43 |
| Travel and Lodging | $1,947.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,538.65 | 2021-2025 | Linq II, Micra, Aurora Ev-Icd Mri Surescan |
| Biosense Webster, INC. | $1,971.15 | 2022-2025 | Carto 3, Qdot Micro Catheter, Thermocool Smarttouch |
| Abbott Laboratories | $265.62 | 2021-2025 | Ensite Precision, Aveir |
| Boston Scientific Corporation | $243.54 | 2022-2025 | Watchman Flx, Resonate El Icd Vr, Watchman |
| Sanofi-Aventis U.S. LLC | $153.98 | 2021-2024 | |
| Philips North America LLC | $148.12 | 2023-2025 | (Am5) Lead Management, (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und |
| Pfizer INC. | $118.17 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $118.08 | 2021-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $101.62 | 2022 | |
| Angiodynamics, INC. | $98.27 | 2024 | Auryon Laser System 100-120 Vac |
| Amgen INC. | $63.61 | 2021-2023 | Repatha |
| Novo Nordisk INC | $55.48 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $55.41 | 2021-2025 | Lokelma, Wainua |
| Merck Sharp & Dohme LLC | $52.19 | 2021-2024 | Verquvo |
| Cvrx, INC. | $44.39 | 2023 | Barostim Neo System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $25.23 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Veryan Medical Incorporated | $24.21 | 2023 | Biomimics 3d Vascular Stent System |
| Kiniksa Pharmaceuticals, LTD. | $20.94 | 2023 | Arcalyst |
| Heartflow, INC. | $20.52 | 2024 | |
| Impulse Dynamics (USA) INC. | $18.82 | 2022 | |
| Bardy Diagnostics, INC. | $16.65 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.77 | 2021 | |
| Lemaitre Vascular, INC. | $11.67 | 2023 | Xenosure Biologic Patch |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Staeci Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.